Q4 2024 EPS Estimates for Zoetis Inc. (NYSE:ZTS) Reduced by Analyst

Zoetis Inc. (NYSE:ZTS) – Equities research analysts at Zacks Research cut their Q4 2024 earnings per share estimates for shares of Zoetis in a report released on Monday, April 29th. Zacks Research analyst E. Bagri now anticipates that the company will earn $1.48 per share for the quarter, down from their prior forecast of $1.50. The consensus estimate for Zoetis’ current full-year earnings is $5.78 per share. Zacks Research also issued estimates for Zoetis’ Q1 2025 earnings at $1.49 EPS, Q2 2025 earnings at $1.65 EPS, FY2025 earnings at $6.38 EPS, Q1 2026 earnings at $1.66 EPS and FY2026 earnings at $6.94 EPS.

Several other research firms have also weighed in on ZTS. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research note on Tuesday, April 23rd. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 price objective (down from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Stifel Nicolaus dropped their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday. StockNews.com lowered shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group increased their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $216.13.

Zoetis Trading Down 0.4 %

Shares of ZTS stock opened at $158.53 on Tuesday. Zoetis has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a quick ratio of 2.00, a current ratio of 3.36 and a debt-to-equity ratio of 1.32. The stock has a 50-day simple moving average of $170.07 and a 200 day simple moving average of $178.97. The stock has a market capitalization of $72.51 billion, a P/E ratio of 31.27, a P/E/G ratio of 2.44 and a beta of 0.85.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The business had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The company’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.15 EPS.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 34.12%.

Insider Activity

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares of the company’s stock, valued at approximately $2,725,267.59. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 2,209 shares of company stock worth $371,293. 0.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Norges Bank acquired a new stake in Zoetis in the 4th quarter valued at about $980,646,000. Price T Rowe Associates Inc. MD raised its holdings in Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock worth $2,707,262,000 after buying an additional 3,244,074 shares during the period. Public Employees Retirement Association of Colorado bought a new stake in Zoetis in the 4th quarter valued at $242,757,000. Vaughan Nelson Investment Management L.P. bought a new stake in shares of Zoetis in the third quarter valued at about $176,219,000. Finally, CIBC Private Wealth Group LLC lifted its stake in Zoetis by 122.6% in the 4th quarter. CIBC Private Wealth Group LLC now owns 1,448,665 shares of the company’s stock valued at $285,923,000 after acquiring an additional 797,884 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.